Phase 2 Evidence and Impact Analysis
Article 1 — Aglatimagene besadenovec + valacyclovir in ICI-refractory NSCLC (PMID 42805763)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Gene therapy + antiviral + ongoing ICI is a mechanistically distinct triple combination not previously evaluated in NSCLC; systemic immune remodeling readout adds novel biological data |
| Clinical Relevance | 8 | Addresses one of oncology's highest unmet needs: ICI-refractory NSCLC. Survival signal in a single-arm Phase 2a is clinically meaningful if confirmed |
| Population Reach | 7 | NSCLC is the #1 cause of cancer death globally; ICI-refractory population is a large, poorly served subset |
| Implementation Speed | 4 | Phase 2a only; requires Phase 2b/3 confirmation, regulatory review, manufacturing scale-up |
| Evidence Strength | 6 | Single-arm Phase 2a (no control arm), abstract-only; encouraging but not practice-changing yet |
Key quantitative result: "Encouraging survival" — exact OS/PFS data not available in abstract; systemic immune remodeling documented but specific metrics not provided. External validation: None — single-arm, single study. Main limitation: No randomized control arm; abstract-level data only; "encouraging" is subjective without reported median OS figures. Equity implications: ICI-refractory patients in community settings or low-resource environments may lack access to this investigational combination; enrollment diversity of the trial is unknown. Evidence Maturity: Exploratory → borderline Validated (Phase 2a with biological plausibility, but single arm; I revise downward from the OpenClaw "Validated" label to Exploratory/Early Validated)
OpenClaw triage_score: 9 | Phase 2 composite: 6.7
Article 2 — Duodeno-ileal magnetic compression anastomosis in metabolic surgery: SR/meta-analysis (PMID 42805885)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Magnetic compression anastomosis is a novel surgical approach, but the systematic review synthesizes existing (limited) data rather than generating new findings |
| Clinical Relevance | 6 | Relevant to bariatric/metabolic surgery; the malnutrition safety signal is clinically important, but comparative data vs. established procedures is thin |
| Population Reach | 7 | Obesity is a global epidemic; bariatric surgery candidates number in the millions; however, this specific technique is not yet widely available |
| Implementation Speed | 3 | Technology adoption requires device approval, surgical training, and longer follow-up data before broad implementation |
| Evidence Strength | 5 | Systematic review of limited, non-comparative prospective cohort data; meta-analysis underpowered for rare adverse events; SNAP malnutrition signal is a safety concern without resolution |
Key quantitative result: Malnutrition signal ("SNAP") identified; no pooled effect sizes on weight loss or metabolic outcomes available in abstract. External validation: Limited — dependent on small primary studies without active controls. Main limitation: No RCT-level data; short follow-up in constituent studies; heterogeneity likely unresolved. Equity implications: Novel device technology will initially concentrate in high-income, tertiary centers; bariatric care is already inequitably distributed by insurance status and geography. Evidence Maturity: Confirmed as Exploratory (OpenClaw labeled "Validated" — I revise downward)
OpenClaw triage_score: 9 | Phase 2 composite: 5.4
Article 3 — Cardio-oncological sequelae of autologous SCT: role of clonal hematopoiesis (PMID 42805147)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Clonal hematopoiesis (CH) as a CV risk factor post-transplant is an active field; this review consolidates and extends the concept but is not first-in-field |
| Clinical Relevance | 6 | Directly relevant to cardio-oncology practice; CH-guided CV monitoring post-SCT could change surveillance protocols |
| Population Reach | 5 | Auto-SCT recipients are a defined but numerically modest population (~50,000/year globally); cardiac events in this group are high-consequence |
| Implementation Speed | 5 | CH testing is increasingly available; the barrier is establishing clinical pathways and evidence thresholds for intervention |
| Evidence Strength | 4 | Observational study design; abstract-only; no effect sizes or sample size reported; medium classification confidence |
Key quantitative result: "Incidence of CV events markedly higher than in general population" — no hazard ratios or absolute rates available in abstract. External validation: The CH-CV link has external biological support from other cohort studies, but this specific study's data are not independently validated. Main limitation: Observational design; potential for residual confounding; no longitudinal CH-monitoring intervention data. Equity implications: CH testing and cardio-oncology subspecialty monitoring are concentrated in academic centers; patients at community hospitals receiving SCT have reduced access to this surveillance. Evidence Maturity: Exploratory (OpenClaw labeled "Validated" — I revise downward given observational design, abstract-only, and medium confidence)
OpenClaw triage_score: 8 | Phase 2 composite: 5.4
Article 4 — HOXA3 deficiency causes congenital athymia and laryngeal malformation (PMID 42805310)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First identification of HOXA3 as a cause of congenital athymia/SCID phenotype; fills a major gap (10% of SCID without known genetic cause) |
| Clinical Relevance | 4 | High novelty but limited immediate clinical actionability — mixed human/animal study; therapeutic path requires substantial development |
| Population Reach | 6 | Relative to the rare disease population and unmet need: congenital athymia is life-threatening with no cure; even small patient numbers have extreme consequence |
| Implementation Speed | 2 | Gene discovery to therapy typically 10+ years; thymic reconstitution therapies exist but HOXA3-specific interventions are early-stage |
| Evidence Strength | 5 | Mixed human-animal model; mechanistic depth is strong; clinical validation in patients is the critical next step; abstract-only |
Key quantitative result: Loss-of-function HOXA3 → cytoplasmic retention of protein → reduced transcriptional activity; ~10% of unexplained SCID potentially explained. External validation: None in this single study; mouse model data supporting human findings strengthens biological plausibility. Main limitation: Animal model dominant; number of human cases with HOXA3 variants not specified in abstract; clinical phenotype spectrum uncertain. Equity implications: Genetic diagnosis of athymia requires advanced sequencing infrastructure; patients in low-resource settings are often diagnosed late or not at all. HOXA3 testing could improve diagnostic yield in consanguineous populations where AR disorders are more frequent. Evidence Maturity: Exploratory (confirmed; mechanistically strong but pre-clinical dominant)
OpenClaw triage_score: 8 | Phase 2 composite: 5.0
Article 5 — ML prediction of arterial stiffness from retinal microvasculature (OCTA) (PMID 42805322)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Integrating OCTA retinal features with clinical parameters via ML for PWV prediction is technically novel; SHAP explainability adds methodological rigor |
| Clinical Relevance | 6 | Arterial stiffness is an important CV biomarker; if validated broadly, non-invasive OCTA-based prediction could expand access |
| Population Reach | 6 | Cardiovascular disease is globally prevalent; arterial stiffness affects millions; OCTA access is currently limited to ophthalmology-resourced settings |
| Implementation Speed | 4 | Needs external validation, prospective clinical testing, and OCTA infrastructure deployment before routine adoption |
| Evidence Strength | 5 | Prospective design is a strength; exclusion criteria for signal quality (OCTA <7, PWV SD >1.5) suggest careful methodology, but abstract-level only; no external validation |
Key quantitative result: Waist circumference, age, and glucose identified as top features via SHAP; retinal texture adds incremental signal; specific AUC/R² not available in abstract. External validation: Not performed — this appears to be a single-center development study. Main limitation: Single-center; no external validation cohort; OCTA availability limits generalizability; unclear how model performs across ethnicities with different retinal vascular baseline anatomy. Equity implications: OCTA is expensive and concentrated in specialized eye clinics; realizing the potential to reduce reliance on PWV equipment requires accessible retinal camera deployment, which favors higher-income settings initially. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; single-center development without external validation)
OpenClaw triage_score: 8 | Phase 2 composite: 5.7
Article 6 — Sybil lung cancer risk model validated in predominantly Black screening cohort (PMID 42805462)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Sybil is a known model; novelty here is external validation in a predominantly Black cohort — clinically important but scientifically incremental |
| Clinical Relevance | 8 | Addresses a direct equity gap in lung cancer screening; validation in a diverse population is essential before guideline adoption |
| Population Reach | 8 | Lung cancer kills ~130,000 Americans annually; current NLST/USPSTF criteria underscreen Black Americans; this model could expand eligible screened populations meaningfully |
| Implementation Speed | 6 | AI screening tools can be deployed without new hardware; integration into existing low-dose CT workflows is feasible within 1–3 years if further validated |
| Evidence Strength | 6 | Retrospective cohort; but multi-institution (implies broader generalizability); abstract-level only |
Key quantitative result: "Robust lung cancer risk prediction" — specific AUC or c-statistic not available in abstract, but described as supporting generalizability. External validation: This study IS the external validation of Sybil beyond its development cohort. Main limitation: Retrospective design; specific performance metrics unavailable; follow-up duration for outcome ascertainment unclear. Equity implications: This is explicitly an equity-advancing paper — Black Americans have historically been underrepresented in lung cancer screening programs and underserved by current eligibility criteria. Positive validation in this population supports broader inclusive screening. Evidence Maturity: Validated (confirmed; external validation of an established model in an underserved population)
🔴🟡 OpenClaw triage_score: 8 | Phase 2 composite: 6.9
Article 7 — Depression, pain, and catastrophizing in sickle cell disease (PMID 42804984)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Depression-pain catastrophizing relationships are established in chronic pain literature; novelty is applying mediation analysis specifically to SCD |
| Clinical Relevance | 7 | SCD chronic pain management is grossly undertreated; integrated behavioral interventions are actionable now |
| Population Reach | 5 | ~100,000 Americans with SCD; globally ~300,000 births/year; disproportionately affects Black and African populations |
| Implementation Speed | 6 | Behavioral interventions for depression/pain are available; integration into SCD care could occur relatively quickly if championed |
| Evidence Strength | 5 | Cross-sectional baseline data from an RCT (GRACE Trial) — methodologically sound for mediation but cannot establish causation; medium classification confidence |
Key quantitative result: Depressive symptoms associated with worse pain both directly and indirectly through catastrophizing (mediation confirmed); specific path coefficients not in abstract. External validation: GRACE Trial baseline data is a reasonable data source but this is observational within the trial. Main limitation: Cross-sectional; cannot determine directionality; catastrophizing measured at single time point; predominantly US-based sample. Equity implications: SCD predominantly affects Black patients who face systemic undertreatment of pain. Identifying psychological targets for intervention is especially important in this context where opioid stigma creates additional barriers. Evidence Maturity: Validated (confirmed — sound mediation analysis, large trial dataset)
🟡 OpenClaw triage_score: 7 | Phase 2 composite: 5.6
Article 8 — CRISPR/Cas14a SAST platform for SNV detection (PMID 42804994)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Split-target design with short ssDNA amplification for Cas14a is a technically creative advance; MAF LOD of 0.00001% is extraordinary if validated in clinical specimens |
| Clinical Relevance | 4 | Impressive bench performance but tested in simulated samples only; clinical validation in patient specimens has not yet occurred |
| Population Reach | 6 | SNV detection spans oncology, pharmacogenomics, and infectious disease — broad theoretical reach; practical reach depends on clinical translation |
| Implementation Speed | 3 | Lab-based proof-of-concept only; regulatory clearance, clinical validation, and instrument development needed |
| Evidence Strength | 4 | In vitro/simulated samples only; no comparison to clinical gold standards in real patient specimens; medium classification confidence |
Key quantitative result: LOD of 100 aM for target DNA; MAF LOD of 0.00001% in simulated samples. External validation: None — single-lab proof-of-concept. Main limitation: Simulated samples only; real clinical matrices (especially plasma ctDNA) introduce substantial interference that may degrade performance; no head-to-head comparison with ddPCR or NGS. Equity implications: If the platform can be simplified to point-of-care format, it could benefit low-resource settings for oncology and infectious disease diagnostics. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; validated in simulation only)
OpenClaw triage_score: 7 | Phase 2 composite: 4.9
Article 9 — LBP as survival and immunotherapy-response marker in hepatocellular carcinoma (PMID 42805112)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | UPR-IFNG axis linked to LBP in LIHC is a specific mechanistic proposal; biomarker discovery in HCC immunotherapy response is competitive but this axis is less explored |
| Clinical Relevance | 4 | Biomarker candidate only; in vitro validation of LBP knockdown; no patient-level prospective validation of immunotherapy prediction |
| Population Reach | 5 | HCC is the 6th most common cancer globally; immunotherapy eligibility is a real clinical bottleneck |
| Implementation Speed | 3 | Candidate biomarker; needs prospective clinical validation, assay standardization, and integration into staging workflows |
| Evidence Strength | 4 | Mixed human-animal cohort; in vitro knockdown data; no prospective clinical validation cohort for immunotherapy prediction |
Key quantitative result: LBP knockdown reduced LIHC cell proliferation in vitro; associations with prognosis and ICB response in cohort analysis (no specific HR/p-values in abstract). External validation: None prospectively. Main limitation: Retrospective cohort and in vitro data; potential for confounding in observational analyses; causality not established; mixed species reduces Clinical Relevance cap to ≤5. Equity implications: HCC disproportionately affects populations with hepatitis B/C in sub-Saharan Africa and East Asia, where immunotherapy access is limited; a predictive biomarker would have greatest value where resources allow selective therapy. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward)
OpenClaw triage_score: 7 | Phase 2 composite: 4.4
Article 10 — HER2 TKIs vs. ADCs in HER2-mutant NSCLC: systematic review/meta-analysis (PMID 42805461)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | The TKI-vs-ADC comparison is a known clinical question; this meta-analysis provides aggregate evidence but does not introduce new biological concepts |
| Clinical Relevance | 8 | Directly practice-informing for oncologists choosing first-line therapy in HER2-mutant NSCLC; sequencing recommendation (TKI first, ADC preserved for later) is actionable |
| Population Reach | 5 | HER2 mutations in NSCLC represent ~2-4% of cases; globally significant given NSCLC incidence |
| Implementation Speed | 7 | Both TKIs (e.g., tucatinib, neratinib) and ADCs (trastuzumab deruxtecan) are approved or available; sequencing guidance can inform practice immediately |
| Evidence Strength | 6 | Systematic review/meta-analysis is strongest design available for this question given absence of head-to-head RCTs; study_design listed as "Prospective Cohort" is likely a pipeline metadata error — actual design is SR/MA |
Key quantitative result: HER2 TKIs showed higher ORR vs. ADCs, especially for YVMA insertions; better safety profile; ADC efficacy preserved after TKI exposure. External validation: Meta-analysis inherently synthesizes multiple studies — cross-validation across trials. Main limitation: No direct head-to-head RCT exists; pooled analyses across heterogeneous trial designs introduce bias; YVMA-specific subgroup may be underpowered. Equity implications: HER2-targeted therapies are expensive and not universally reimbursed; the sequencing insight favoring TKIs first (lower cost in some markets) could have equity benefits if cost differential exists. Evidence Maturity: Validated (confirmed — meta-analytic synthesis of available trial data)
🟠 OpenClaw triage_score: 7 | Phase 2 composite: 6.2
Article 11 — Pancreatic cystic lesion guideline concordance for malignancy risk prediction (PMID 42805547)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Comparative guideline evaluation is methodologically straightforward; findings (high concordance for high-risk lesions) are reassuring but not surprising |
| Clinical Relevance | 7 | PCL management is a common clinical dilemma; knowing major guidelines agree on high-risk features reduces decision uncertainty |
| Population Reach | 6 | PCLs are found in ~2-3% of CT scans; prevalence increases with age; millions of incidental findings detected annually |
| Implementation Speed | 7 | No new technology needed; findings support confidence in existing guidelines; can inform practice immediately |
| Evidence Strength | 5 | Retrospective cohort using routinely reported radiology features; abstract-only; specific concordance statistics not available |
Key quantitative result: "Strong concordance for high-risk lesion identification" — specific kappa or sensitivity/specificity not reported in abstract. External validation: Guideline comparison inherently tests existing validated frameworks against outcome data. Main limitation: Retrospective; long-term outcome data quality depends on completeness of follow-up; performance for intermediate-risk lesions (the clinical challenge) is unclear. Equity implications: Standardized guideline application could reduce variability in PCL management between high- and low-volume centers. Evidence Maturity: Validated (confirmed)
OpenClaw triage_score: 7 | Phase 2 composite: 5.8
Article 12 — Sarcopenia in CKD patients in Northwest Ethiopia (PMID 42805656)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Sarcopenia-CKD associations are established; novel contextual contribution is Sub-Saharan African population data, which is underrepresented |
| Clinical Relevance | 5 | Frailty-CKD-oxidative stress associations suggest targets; practical interventions not yet defined |
| Population Reach | 6 | CKD affects ~10% of adults globally; sarcopenia prevalence in African CKD populations is poorly characterized — data gap is meaningful |
| Implementation Speed | 5 | Sarcopenia assessment tools exist; nutritional and exercise interventions are low-cost and deployable |
| Evidence Strength | 4 | Cross-sectional observational; cannot establish causality; single renal clinic in Ethiopia limits generalizability even within the region; medium classification confidence |
Key quantitative result: Frailty correlation r=0.566 (p<0.001); eGFR correlation r=0.260 (p=0.004); antioxidant capacity r=0.455 (p<0.001) — moderate-to-strong correlations. External validation: None in this study. Main limitation: Cross-sectional design; single-center; cannot determine whether sarcopenia precedes or follows CKD progression. Equity implications: Provides rare data on CKD burden in low-income Sub-Saharan African settings — directly relevant to an underserved population. However, interventional evidence in this context is still lacking. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; cross-sectional, single site)
🟡 OpenClaw triage_score: 7 | Phase 2 composite: 4.8
Article 13 — Total diet replacement for obesity-related cancer risk in women (PMID 42805663)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TDR programs are established; the novelty is focusing on women at elevated breast/endometrial cancer risk due to obesity |
| Clinical Relevance | 7 | Obesity-related cancer prevention is highly actionable; TDR is a feasible, deployable intervention |
| Population Reach | 7 | Millions of women globally live with obesity and elevated breast/endometrial cancer risk |
| Implementation Speed | 6 | TDR programs exist and can be implemented within existing weight management infrastructure |
| Evidence Strength | 5 | Prospective cohort, UK-based, with meaningful dropout analysis; no control arm; long-term cancer incidence outcomes not yet available |
Key quantitative result: Mean BMI of completers 36.2 kg/m²; dropout demographics available; cancer incidence endpoint not yet reported. External validation: Complements existing TDR and caloric restriction literature. Main limitation: No control arm; short 12-month window with cancer outcomes not yet measurable; dropout rate (56% of some group lost to follow-up) is substantial. Equity implications: TDR programs require access to meal replacement products that may be cost-prohibitive for lower-income women; the women at highest obesity-related cancer risk are disproportionately in lower socioeconomic groups. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; no comparator, cancer outcomes not yet available)
🔴 OpenClaw triage_score: 7 | Phase 2 composite: 5.9
Article 14 — NT-proBNP testing cost-effectiveness for HF prevention in older T2DM adults (PMID 42805765)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | NT-proBNP screening in diabetes is not new; health economic modeling is the contribution here |
| Clinical Relevance | 8 | Cost-effectiveness evidence is exactly what's needed to drive guideline uptake; Medicare perspective is directly policy-relevant |
| Population Reach | 8 | Adults ≥65 with T2DM represent tens of millions in the US alone; HF is the leading cause of hospitalization in this group |
| Implementation Speed | 7 | NT-proBNP testing is widely available, inexpensive, and already used in cardiology; adding it to routine diabetes care is low-barrier |
| Evidence Strength | 5 | Economic modeling study — dependent on input assumptions; medium classification confidence; no prospective intervention arm |
Key quantitative result: NT-proBNP testing group: lifetime cost US$117,010 vs. $92,283 in standard care — higher cost but longer survival and more appropriate cardioprotective treatment use (cost-effective if ICER falls below WTP threshold, as appears to be the case). External validation: Sensitivity analyses confirmed robustness. Main limitation: Modeled, not empirical; results are only as valid as input parameters; does not capture real-world adherence to cardioprotective treatments triggered by elevated NT-proBNP. Equity implications: Medicare-focused — may not reflect Medicaid or uninsured populations. NT-proBNP access in primary care is variable; rural/underserved T2DM patients may not benefit equally. Evidence Maturity: Validated (confirmed — well-executed health economic model)
🟢 OpenClaw triage_score: 7 | Phase 2 composite: 6.6
Article 15 — Mortality and risk factors in obesity hypoventilation syndrome, Afro-Caribbean cohort (PMID 42805766)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | OHS risk factors in predominantly Afro-Caribbean populations is underrepresented in the literature; acute RF presentation as a mortality driver is a specific finding |
| Clinical Relevance | 6 | Risk stratification for OHS is clinically useful; findings support early diagnosis and better CV risk management |
| Population Reach | 5 | OHS is a significant but numerically smaller condition vs. OSA generally; Afro-Caribbean-specific data fills an equity gap |
| Implementation Speed | 6 | Risk factor identification (irregular follow-up, left heart disease, low hematocrit) maps to existing clinical interventions |
| Evidence Strength | 6 | Prospective design elements with Cox regression; multivariable adjustment; clear outcome data (5-yr mortality 12.6%); medium classification confidence |
Key quantitative result: 5-year mortality 12.6%; acute RF at diagnosis HR 6.60 (95% CI 1.50–29.10); irregular follow-up HR 5.0 (1.82–14.29); left heart disease HR 3.63 (1.51–8.70). External validation: None — single center in Martinique. Main limitation: Single-center; Martinique population may not generalize to other Afro-Caribbean or African-American OHS populations; wide CIs suggest small sample for some subgroups. Equity implications: Provides rare data on an underserved Caribbean population with high obesity burden; irregular follow-up as a top mortality predictor highlights systemic access problems. Evidence Maturity: Validated (confirmed — prospective outcome data with Cox modeling)
🟡 OpenClaw triage_score: 7 | Phase 2 composite: 5.5
Article 16 — Taiwan 2025 consensus guidelines for gastric cancer (PMID 42805853)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Guidelines are expert consensus, not original research; adapts existing evidence to local context |
| Clinical Relevance | 7 | Highly relevant to Taiwanese oncology practice; Delphi-based consensus on 23 clinical questions provides structured decision support |
| Population Reach | 5 | Taiwan-specific; gastric cancer remains a significant burden in East Asia broadly |
| Implementation Speed | 8 | Guidelines are immediately applicable to clinical practice in Taiwan; no additional evidence required |
| Evidence Strength | 4 | Consensus document — evidence quality depends on underlying studies; Delphi process adds structured expert agreement but not new data |
Key quantitative result: 23 key clinical questions addressed; no primary data. External validation: Draws on existing global trial evidence. Main limitation: Geographic scope limited to Taiwan; local practice patterns may not reflect other Asian countries; potential for expert opinion to override weak evidence. Equity implications: Locally adapted guidelines improve care equity within Taiwan by aligning with available resources and patient population characteristics. Evidence Maturity: Validated (confirmed — though "validated" here means evidence-based consensus, not original research confirmation)
OpenClaw triage_score: 7 | Phase 2 composite: 5.0
Article 17 — Preoperative anaemia and iron deficiency in Wales: national retrospective cohort (PMID 42805893)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Pre-operative anaemia and poor outcomes is well-established; national-level data from Wales adds population evidence |
| Clinical Relevance | 8 | Pre-operative iron deficiency is highly modifiable; national data strengthens the case for routine pre-operative blood optimization programs |
| Population Reach | 8 | Major elective surgery affects millions annually; anaemia prevalence is ~30-40% in surgical patients |
| Implementation Speed | 8 | Pre-operative iron infusion is an existing, available, low-cost intervention; implementation through Patient Blood Management programs is feasible now |
| Evidence Strength | 6 | National retrospective cohort is a methodological strength; high-confidence classification; specific effect sizes for iron deficiency with inflammation not in abstract |
Key quantitative result: Iron deficiency and anaemia with inflammation associated with "particularly poor outcomes" — specific mortality HRs not available in abstract. External validation: Consistent with prior studies; national-scale data adds confirmatory weight. Main limitation: Retrospective; iron deficiency classification may vary by institutional lab thresholds; outcomes not granularly reported in abstract. Equity implications: Pre-operative anaemia is more prevalent in lower-income patients, women, elderly, and patients with chronic disease. A national data-driven case for blood optimization programs could reduce surgical outcome disparities. Evidence Maturity: Validated (confirmed)
🟢 OpenClaw triage_score: 7 | Phase 2 composite: 6.7
Article 18 — Sleep apnea airway collapse phenotypes and cardiometabolic comorbidity (PMID 42805916)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | DISE phenotyping in OSA is established; linking collapse patterns to cardiometabolic risk is logical but not novel in concept |
| Clinical Relevance | 4 | Association did not survive multiplicity correction — main finding is essentially null; limited direct practice implications |
| Population Reach | 5 | OSA affects ~1 billion people; cardiometabolic risk in OSA is a major clinical concern |
| Implementation Speed | 3 | Null result after correction means no immediate practice change is warranted |
| Evidence Strength | 5 | Retrospective; single-center; n=355; significance lost after correction — honest reporting is a methodological strength |
Key quantitative result: Association between airway collapse phenotype and cardiometabolic comorbidity not significant after Bonferroni/multiplicity correction. External validation: None. Main limitation: Single-center; small sample; null result may reflect underpowering rather than true absence of association. Equity implications: Neutral. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; null result with multiplicity correction)
OpenClaw triage_score: 7 | Phase 2 composite: 4.2
Article 19 — First-trimester CBC inflammatory indices for miscarriage prediction (PMID 42802638)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | NLR/PLR/SII/SIRI for miscarriage prediction is an active area; combination model with clinical factors adds incremental value |
| Clinical Relevance | 5 | If externally validated, routine CBC-based risk stratification in early pregnancy is highly feasible |
| Population Reach | 6 | Miscarriage affects ~15% of recognized pregnancies; CBC is a routine test universally available |
| Implementation Speed | 6 | CBC is already performed; adding calculated indices requires only software/protocol changes |
| Evidence Strength | 4 | Retrospective; internal validation only; no external validation; single-center |
Key quantitative result: Combination model (age + gestational age + CBC indices) provided "significant improvement in discrimination" — specific AUC improvement not in abstract. External validation: None — internal validation only. Main limitation: Internal validation only; single-center; retrospective; no external cohort tested. Equity implications: CBC is universally available — if validated, this could benefit all pregnant patients including those in low-resource settings. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; internal validation only)
OpenClaw triage_score: 6 | Phase 2 composite: 5.1
Article 20 — CALLY index and multisystem diseases: phenome-wide Mendelian randomization (PMID 42803832)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Applying MR to a composite inflammation/nutrition/immunity index across a phenome-wide screen is methodologically interesting |
| Clinical Relevance | 4 | Causal claims from MR for a composite index across multiple disease domains require substantial validation before practice change |
| Population Reach | 6 | CALLY index components (CRP, albumin, lymphocyte) are routinely measured — if validated, broad applicability |
| Implementation Speed | 4 | MR findings require prospective intervention trials to confirm utility; composite index calculation is trivial if validated |
| Evidence Strength | 5 | MR is a robust causal inference method when assumptions are met; however, composite biomarkers introduce pleiotropy concerns; medium classification confidence |
Key quantitative result: CALLY causally associated with neurodegenerative, metabolic, and sleep disorders (specific OR/HR values not in abstract). External validation: MR inherently uses genetic instruments as instrumental variables — methodological proxy for experimental evidence. Main limitation: Pleiotropy risk with a composite index; MR assumptions (no horizontal pleiotropy) need explicit testing; phenome-wide approach increases type I error risk. Equity implications: Components of CALLY are routinely available in all clinical settings — broad potential equity benefit if validated. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; MR findings require prospective validation)
OpenClaw triage_score: 6 | Phase 2 composite: 5.0
Article 21 — Prostate cancer screening alignment with likelihood of benefit: VA vs. FFS Medicare (PMID 42804174)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | VA healthcare system performance on guideline alignment is a known topic; this adds updated data comparing two payer systems |
| Clinical Relevance | 7 | Overscreening in men least likely to benefit is a persistent quality problem; VA's lower testing rates in this group support value-based care arguments |
| Population Reach | 7 | PSA testing affects millions of men annually; VA system serves ~9 million veterans |
| Implementation Speed | 7 | Policy/protocol changes within payer systems are achievable within years; FFS Medicare could adopt VA-like risk-stratified approaches |
| Evidence Strength | 6 | Retrospective cohort; JAMA Internal Medicine — high-quality journal; VA data linkage is robust |
Key quantitative result: VA associated with lower PSA testing AND biopsy rates in men least likely to benefit vs. FFS Medicare — specific rate differences not in abstract. External validation: Consistent with known VA guideline adherence literature. Main limitation: Retrospective; confounding by patient characteristics between VA and FFS populations; "likelihood of benefit" operationalization not described in abstract. Equity implications: The VA system demonstrates better alignment of high-intensity screening with those who benefit — a potential model for equity-informed screening policy. FFS Medicare's higher testing rates in men unlikely to benefit may reflect financial incentives inherent to fee-for-service payment. Evidence Maturity: Validated (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 6.1
Article 22 — Sjögren's syndrome-associated retinal vasculitis: case report (PMID 42804597)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Exceptionally rare presentation; case report adds to sparse literature |
| Clinical Relevance | 4 | Case report; low generalizability but relevant to specialist ophthalmologists managing Sjögren's |
| Population Reach | 2 | Ultra-rare complication of a rare condition |
| Implementation Speed | 3 | Requires much more evidence before clinical protocol changes |
| Evidence Strength | 2 | Case report (n=1); lowest design level |
Key quantitative result: N=1 case; no quantitative outcomes. Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 3.2
Article 23 — Cranial neuropathies diagnostic framework review (PMID 42804727)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Narrative review of established categories; no new data |
| Clinical Relevance | 6 | Integrated diagnostic framework is useful for generalist neurologists; rare disease context is clinically relevant |
| Population Reach | 4 | Cranial neuropathies are encountered regularly but specific rare causes affect small populations |
| Implementation Speed | 7 | Framework immediately applicable to clinical practice |
| Evidence Strength | 3 | Narrative review — no primary data |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 4.6
Article 24 — Patient willingness to de-escalate adjuvant therapy by biomarker results in melanoma (PMID 42804856)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Patient preference studies around biomarker-guided de-escalation are increasingly common; health literacy stratification adds nuance |
| Clinical Relevance | 6 | Shared decision-making for treatment de-escalation is directly practice-relevant as predictive biomarkers emerge in melanoma |
| Population Reach | 5 | Melanoma incidence rising; adjuvant immunotherapy decisions affect thousands annually |
| Implementation Speed | 6 | Patient education tools are deployable now |
| Evidence Strength | 4 | Cross-sectional survey; medium classification confidence |
Key quantitative result: Lower health literacy OR 0.61 (p=0.045) vs. academic degree OR 2.31 (p=0.037) for willingness to forgo therapy. Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 4.9
Article 25 — AI-powered liquid crystal biosensor for CA125 ovarian cancer detection (PMID 42804995)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Dual-frequency liquid crystal DSM with AI readout for CA125 is technically novel; 3-second response is notable |
| Clinical Relevance | 3 | In vitro only; not tested in patient cohorts; CA125 alone has known specificity limitations |
| Population Reach | 5 | Ovarian cancer is devastating and late-diagnosed; better CA125 detection could help — but CA125 specificity problems limit population benefit |
| Implementation Speed | 3 | Pre-clinical technology; regulatory pathway and clinical validation years away |
| Evidence Strength | 3 | In vitro proof-of-concept; LOD achieved in deionized water vs. human serum (4.86 ng/mL) — performance degrades in matrix |
Key quantitative result: LOD 0.82 ng/mL in water, 4.86 ng/mL in human serum for CA125. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; in vitro only)
OpenClaw triage_score: 6 | Phase 2 composite: 3.9
Article 26 — LILRB3 as context-dependent immune checkpoint and therapeutic target (review) (PMID 42805065)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | iPRR framework positioning of LILRB3 as a context-dependent checkpoint is conceptually novel; bridges immunology, neurology, and oncology |
| Clinical Relevance | 3 | Review; no clinical data; therapeutic relevance is prospective |
| Population Reach | 4 | Theoretical broad reach across cancer and neurological conditions |
| Implementation Speed | 2 | Basic science review; drug development horizon is distant |
| Evidence Strength | 3 | Narrative review; no primary data |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 3.9
Article 27 — BRSK1 monoallelic variants in neurodevelopmental disorder with/without epilepsy (PMID 42805187)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | New gene-disease association in an AMJHG publication; BRSK1/SAD-B in human disease is a meaningful advance |
| Clinical Relevance | 4 | Mixed human/animal study; clinical utility requires clinical validation of variant pathogenicity; cap ≤5 per non-human model dominant design |
| Population Reach | 5 | Rare neurodevelopmental disorder; unmet diagnostic need is high relative to affected population |
| Implementation Speed | 2 | Gene discovery to diagnostic utility: 5–10 years minimum |
| Evidence Strength | 5 | Drosophila and human cohort combined; American Journal of Human Genetics — peer-reviewed; mechanistic depth |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 4.3
Article 28 — ML models for suspected pulmonary embolism in EDs: multicentre diagnostic study (PMID 42805256)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ML for PE diagnosis is a well-trodden area; the pre+post test combination (ridge + random forest) is methodologically thoughtful |
| Clinical Relevance | 7 | PE diagnosis in EDs is high-stakes; reducing unnecessary imaging (54.1% vs. 66.8% with PERC) without sacrificing safety is clinically meaningful |
| Population Reach | 7 | PE is the 3rd most common acute cardiovascular syndrome; millions of ED presentations annually |
| Implementation Speed | 5 | Multicentre development is promising; prospective clinical validation and EHR integration needed |
| Evidence Strength | 6 | Multicentre retrospective; failure rate 1.44% (95% CI 1.04–1.99) — within acceptable safety thresholds; high classification confidence |
Key quantitative result: Failure rate 1.44%; imaging proportion 54.1% vs. PERC 66.8% (12.7% absolute reduction in imaging); MCC 0.470. Evidence Maturity: Validated (confirmed — multicentre retrospective with quantified safety metrics)
OpenClaw triage_score: 6 | Phase 2 composite: 6.0
Article 29 — Leniolisib and rapamycin in APDS: ESID registry analysis (PMID 42805311)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Real-world leniolisib (PI3Kδ inhibitor) data in APDS is new; direct comparison with rapamycin in a registry is valuable given paucity of controlled data |
| Clinical Relevance | 7 | APDS is a rare disease with high morbidity; leniolisib is FDA-approved; real-world safety and efficacy data directly inform prescribing |
| Population Reach | 5 | Rare disease — relative to the affected population and unmet need, this is high-impact data |
| Implementation Speed | 6 | Leniolisib is approved; findings support its use over rapamycin based on tolerability |
| Evidence Strength | 6 | Registry-based retrospective cohort; large collaborative (ESID); no randomization; but real-world comparative data in an orphan disease is meaningful |
Key quantitative result: Leniolisib and rapamycin both reduced benign lymphoproliferation; treatment-limiting adverse events only with rapamycin. Evidence Maturity: Validated (confirmed)
🟠 OpenClaw triage_score: 6 | Phase 2 composite: 6.0
Article 30 — Tumor-infiltrating B cells in cancer immunity (review) (PMID 42805356)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TIL-B biology is a growing field; heterogeneity/spatial organization framing adds conceptual structure |
| Clinical Relevance | 4 | Review only; no clinical data; therapeutic implications are future-oriented |
| Population Reach | 5 | Cancer broadly |
| Implementation Speed | 2 | Basic science review |
| Evidence Strength | 3 | Narrative review |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 3.9
Article 31 — Menin inhibitors in AML: mechanisms and clinical pharmacology (review) (PMID 42805358)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Menin inhibitor mechanisms are established; comparative pharmacology across agents is clinically useful but incremental |
| Clinical Relevance | 7 | Helps clinicians select and individualize menin inhibitor therapy in a rapidly evolving treatment landscape |
| Population Reach | 4 | NPM1/KMT2A-rearranged AML is a defined subset; high-consequence disease but numerically limited |
| Implementation Speed | 6 | Multiple agents are in late-stage trials or approved; pharmacological guidance is immediately applicable |
| Evidence Strength | 4 | Review; no primary data |
Evidence Maturity: Exploratory (confirmed — review)
OpenClaw triage_score: 6 | Phase 2 composite: 5.1
Article 32 — Emerging targeted therapies in metastatic melanoma beyond BRAF/MEK (review) (PMID 42805360)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Reviews emerging strategies (degraders, ADCs); protein degradation platforms are genuinely novel |
| Clinical Relevance | 6 | Useful landscape review for oncologists managing post-ICI/BRAF-refractory melanoma |
| Population Reach | 5 | Melanoma incidence increasing; BRAF-mutant/ICI-refractory is the clinical gap |
| Implementation Speed | 3 | Most emerging strategies are pre-approval |
| Evidence Strength | 3 | Narrative review; no primary data |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 4.5
Article 33 — ASXL1 CHIP and lung cancer risk (PMID 42805460)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Gene-specific CHIP (ASXL1) linked to solid cancer (lung) is a meaningful advance; smoking × CHIP interaction is novel |
| Clinical Relevance | 5 | Mechanistically compelling but not yet clinically actionable; CHIP testing for lung cancer risk is not standard |
| Population Reach | 7 | Lung cancer is the #1 cancer killer; CHIP is common (>10% of people over 60); smokers are a vast at-risk population |
| Implementation Speed | 4 | CHIP sequencing for cancer risk stratification requires validation trials before clinical deployment |
| Evidence Strength | 5 | Cohort study; high confidence classification; gene-specific analysis is a strength; no functional mechanistic data in abstract |
Key quantitative result: ASXL1-mutant CHIP (smoking-associated expansion) linked to increased lung cancer risk — specific OR/HR not in abstract. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; observational, mechanism not fully established)
🔴 OpenClaw triage_score: 6 | Phase 2 composite: 5.5
Article 34 — NHS England Diabetes Prevention Programme cost-effectiveness in Canada (PMID 42805627)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | DPP cost-effectiveness is established; Canada-specific modeling extends existing evidence |
| Clinical Relevance | 7 | Policy-level relevance: cost-effectiveness evidence supports adoption by Canadian public health system |
| Population Reach | 8 | Prediabetes affects ~10% of adults; millions in Canada and globally |
| Implementation Speed | 7 | NHS program structure exists; implementation in Canada requires system-level policy rather than clinical innovation |
| Evidence Strength | 5 | Modeled; sensitivity analyses are a strength; no primary outcomes data |
Evidence Maturity: Validated (confirmed — robust modeling with sensitivity analyses)
🟢 OpenClaw triage_score: 6 | Phase 2 composite: 6.2
Article 35 — Women in their 40s and USPSTF mammography guideline update (focus groups) (PMID 42805646)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Qualitative focus group study; patient preferences around screening guidelines are a known topic |
| Clinical Relevance | 6 | Patient preference data is essential for guideline implementation; emphasis on informed choice is directly relevant to shared decision-making practice |
| Population Reach | 7 | USPSTF guideline affects all US women aged 40–49 (~20 million) |
| Implementation Speed | 7 | Can immediately inform how clinicians communicate about mammography in clinical encounters |
| Evidence Strength | 4 | Qualitative focus group; medium classification confidence; not generalizable beyond the study sample |
Key quantitative result: Women strongly prioritized being informed about benefits AND harms despite reduced USPSTF emphasis on informed choice. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise; qualitative design, small N)
🟢 OpenClaw triage_score: 6 | Phase 2 composite: 5.7
Article 36 — CD19 CAR-T vs. blinatumomab in relapsed/refractory B-ALL: comparative study (PMID 42805761)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Single-cell profiling alongside clinical comparison adds biological depth to an important clinical question |
| Clinical Relevance | 8 | Direct head-to-head comparative data for two approved therapies in r/r B-ALL is exactly what clinicians need for treatment selection |
| Population Reach | 5 | r/r B-ALL is a defined patient population; outcomes are catastrophic without effective rescue therapy |
| Implementation Speed | 6 | Both therapies are available; findings support CAR-T preference in high burden/relapsed disease |
| Evidence Strength | 5 | Comparative study (non-randomized); mixed species metadata likely an error (human study); abstract-level |
Key quantitative result: CAR-T associated with higher CR/CRi rate vs. blinatumomab, particularly in high tumor burden and relapsed disease, despite higher severe toxicity. Evidence Maturity: Validated (confirmed — comparative clinical study with single-cell mechanistic data)
🟠 OpenClaw triage_score: 6 | Phase 2 composite: 6.0
Article 37 — Pre-diagnostic CT body composition changes in pancreatic cancer (PMID 42805808)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Longitudinal pre-diagnostic body composition trajectories from CT as PDAC signals is genuinely novel; SFI decline distinguishes cases from controls |
| Clinical Relevance | 5 | Intriguing early detection signal but requires prospective validation; not immediately actionable |
| Population Reach | 5 | PDAC kills ~90% within 5 years; earlier detection is critically needed; retroactively measurable from existing CT data |
| Implementation Speed | 4 | Would require AI-assisted CT body composition analysis at scale; prospective validation needed first |
| Evidence Strength | 5 | Retrospective cohort; matched controls; high confidence; longitudinal design is a strength but selection bias risk |
Key quantitative result: PDAC cases showed steeper decline in SFI (-0.53 cm — unit likely cm²/m²) vs. matched controls prior to diagnosis. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; retrospective, no prospective validation)
🔴 OpenClaw triage_score: 6 | Phase 2 composite: 5.2
Article 38 — Rectal cancer with downstaged lateral pelvic lymph nodes after total neoadjuvant therapy (PMID 42805858)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | LPLN downstaging by TNT is an emerging area; this adds to the evidence base that complete responders have favorable outcomes |
| Clinical Relevance | 8 | Challenging the dogma that LPLN positivity predicts poor outcomes when complete response is achieved has direct surgical planning implications |
| Population Reach | 5 | Rectal cancer with LPLN involvement is a specific subset; clinical impact concentrated in colorectal surgical practice |
| Implementation Speed | 6 | Findings can inform immediate clinical discussions about surgery vs. watch-and-wait in LPLN-complete responders |
| Evidence Strength | 5 | Retrospective cohort; high classification confidence; no randomization; abstract-level |
Key quantitative result: Baseline LPLN positivity NOT associated with worse oncologic outcomes in complete responders — in both TME and watch-and-wait groups. Evidence Maturity: Validated (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 5.9
Article 39 — DD-GAN virtual elastography for thyroid cancer diagnosis (PMID 42805865)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Generating virtual elastography from standard ultrasound via GAN is technically creative; addresses real clinical gap in portable device capability |
| Clinical Relevance | 6 | Improved TI-RADS AUC for both junior and senior radiologists has practical value; democratizes elastography |
| Population Reach | 6 | Thyroid nodules are extremely common; millions of biopsies performed annually |
| Implementation Speed | 4 | Needs prospective multicenter validation; FDA/CE clearance pathway |
| Evidence Strength | 5 | Prospective cohort; single-center; high classification confidence; specific AUC improvement not in abstract |
Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; single-center, no external validation)
OpenClaw triage_score: 6 | Phase 2 composite: 5.7
Article 40 — Bamboo nodes of vocal cords and autoimmune disease (PMID 42805898)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Largest retrospective series (n=44) of bamboo nodes; autoimmune screening recommendation is a practical advance for a rare entity |
| Clinical Relevance | 5 | Rare condition; practical guidance for ENT and rheumatology practice |
| Population Reach | 2 | Rare condition |
| Implementation Speed | 6 | Screening recommendation is immediately implementable |
| Evidence Strength | 4 | Retrospective; n=44; high dropout in speech therapy follow-up (56%) |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 6 | Phase 2 composite: 4.3
Article 41 — Pre-operative biochemical algorithm for uterine sarcoma risk stratification (PMID 42805899)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Pre-operative biochemical sarcoma risk model that reclassifies some high-risk to lower-risk is clinically meaningful; avoids unnecessary radical surgery |
| Clinical Relevance | 7 | Reducing unnecessary radical surgery in women with uterine masses is a direct patient benefit; 92.3% accuracy is promising |
| Population Reach | 5 | Uterine sarcoma is uncommon but devastating; uterine masses requiring pre-operative risk stratification are common |
| Implementation Speed | 5 | Biochemical tests are available; requires external validation before widespread adoption |
| Evidence Strength | 5 | Retrospective cohort; internal validation; 92.2% specificity, 92.3% accuracy — impressive if confirmed; no external validation |
Key quantitative result: Specificity 92.2%, overall accuracy 92.3%; subset reclassified from high-risk to lower-risk. Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; internal validation only)
OpenClaw triage_score: 6 | Phase 2 composite: 5.7
Article 42 — Automated QA of brain CT/MR image registration using 3D CNN (PMID 42805906)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Automated μ-score for registration QA is technically novel; addresses a real workflow gap in stereotactic radiotherapy |
| Clinical Relevance | 5 | Patient safety implication if registration errors are caught automatically; but clinical workflow adoption is the barrier |
| Population Reach | 5 | Brain radiotherapy patients are a defined but numerically modest group |
| Implementation Speed | 5 | AI QA tools can be embedded in treatment planning systems; prospective clinical deployment needed |
| Evidence Strength | 5 | Cohort study with clinical cases tested; single-center; high classification confidence |
Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; single-center proof-of-concept)
OpenClaw triage_score: 6 | Phase 2 composite: 5.3
Article 43 — Deep learning synthetic CT for pelvic radiotherapy planning (PMID 42805915)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | MRI-only workflow via sCT is an active area; pelvic application extends existing head/neck work |
| Clinical Relevance | 5 | MRI-only planning reduces radiation exposure and registration errors; bony structure MAE (17-19 HU) is a meaningful limitation |
| Population Reach | 5 | Pelvic radiation is common (prostate, cervical, rectal cancer) |
| Implementation Speed | 5 | sCT tools approaching clinical readiness; regulatory clearance is the primary barrier |
| Evidence Strength | 5 | Retrospective; single-center; error metrics reported; high classification confidence |
Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward)
OpenClaw triage_score: 6 | Phase 2 composite: 5.3
Article 44 — Breast cancer screening strategies for South Asian women in Australia (PMID 42805923)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Culturally sensitive outreach is a well-established concept; this study documents strategies and cultural training needs |
| Clinical Relevance | 6 | Directly relevant to healthcare provider practice for diverse patient populations |
| Population Reach | 6 | South Asian diaspora globally; breast cancer screening inequities are widespread |
| Implementation Speed | 7 | Culturally competent communication tools can be adopted immediately |
| Evidence Strength | 4 | Qualitative observational; medium classification confidence |
Evidence Maturity: Exploratory (OpenClaw "Validated" — I revise downward; qualitative design)
🟡 OpenClaw triage_score: 6 | Phase 2 composite: 5.5
Article 45 — NLR for severe saphenous vein reflux in chronic venous insufficiency (PMID 42803118)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | NLR in CVI is explored; grading-specific analysis within CEAP is incremental |
| Clinical Relevance | 5 | If NLR can identify Grade IV disease from routine CBC, it adds a low-cost staging tool |
| Population Reach | 5 | CVI is common (~25% of adults); severe reflux affects a meaningful subset |
| Implementation Speed | 6 | CBC is universally available; NLR calculation is trivial |
| Evidence Strength | 4 | Retrospective; high classification confidence; Benjamini-Hochberg correction applied (methodological strength); single-center |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 5 | Phase 2 composite: 4.8
Article 46 — HLA-DQA1/HLA-DQB1 immune signatures in CAR-T-treated DLBCL (PMID 42805113)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | m6A × HLA-DQ × CAR-T response at single-cell resolution is mechanistically sophisticated |
| Clinical Relevance | 4 | Small clinical validation cohort (n=26); not yet actionable |
| Population Reach | 5 | DLBCL/CAR-T eligible population is defined; 30-40% of CAR-T patients relapse or are refractory |
| Implementation Speed | 3 | Mechanistic discovery; clinical assay development needed |
| Evidence Strength | 4 | Small clinical validation (n=15 responders, n=11 non-responders); exploratory maturity is confirmed |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 5 | Phase 2 composite: 4.6
Article 47 — Periprosthetic fractures: growing challenge review (PMID 42805168)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 2 | Standard review of a known clinical challenge |
| Clinical Relevance | 5 | Practically useful reference for orthopedic surgeons |
| Population Reach | 6 | Aging population with rising total joint replacements makes periprosthetic fractures increasingly common |
| Implementation Speed | 5 | No new interventions proposed |
| Evidence Strength | 2 | Review article; no primary data |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 5 | Phase 2 composite: 4.2
Article 48 — ZAP-70 as prognostic biomarker in CLL (review) (PMID 42805448)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | ZAP-70 is a well-characterized CLL biomarker; this review synthesizes known limitations |
| Clinical Relevance | 5 | Adjunctive use when molecular testing is unavailable is a pragmatic clinical niche |
| Population Reach | 5 | CLL is the most common adult leukemia in Western countries |
| Implementation Speed | 5 | ZAP-70 testing by flow cytometry is available now in some centers |
| Evidence Strength | 3 | Narrative review; no primary data |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 5 | Phase 2 composite: 4.1
Article 49 — Regional citrate + nafamostat anticoagulation for CKRT in septic AKI: trial protocol (PMID 42805649)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Combination anticoagulation for CKRT circuit preservation is rational; three-arm design adds scientific rigor |
| Clinical Relevance | 7 | Circuit lifespan in CKRT is a real operational problem; combination strategy could meaningfully improve care |
| Population Reach | 5 | Septic AKI requiring CKRT is common in ICUs globally |
| Implementation Speed | 3 | Protocol only; trial results needed; 2–5+ years before conclusions |
| Evidence Strength | 3 | Protocol publication — no results; cap at 3 |
Evidence Maturity: Exploratory (confirmed — protocol)
🟢 OpenClaw triage_score: 5 | Phase 2 composite: 4.9
Article 50 — PARP3 promotes SARS-CoV-2 replication; venadaparib interaction (PMID 42805913)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PARP3 as a pro-viral factor in SARS-CoV-2 is a novel mechanism |
| Clinical Relevance | 3 | In vitro cell model; medium classification confidence; not human clinical data |
| Population Reach | 5 | COVID-19 antivirals remain relevant globally |
| Implementation Speed | 3 | Pre-clinical; drug repurposing pathway still requires clinical trials |
| Evidence Strength | 3 | In vitro cell culture only; medium confidence |
Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 5 | Phase 2 composite: 4.0
Article 51 — Autophagy flux remodeled by sex and cell type in human aging (PMID 42802483)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Challenges the assumption that autophagy uniformly declines with age; sex- and cell-type-specific remodeling is a meaningful conceptual advance |
| Clinical Relevance | 3 | Mechanistic basic science; pilot exercise intervention in PBMC is suggestive but not practice-changing |
| Population Reach | 5 | Aging affects everyone; autophagy is a broad biological process |
| Implementation Speed | 3 | Basic science discovery; translation pathway unclear |
| Evidence Strength | 4 | Cohort study + pilot intervention; human cell data; Aging Cell journal; high confidence; but n is small for pilot intervention |
Key quantitative result: 12 weeks mild exercise → decreased PBMC autophagy flux + improved physical function (pilot; no statistical details in abstract). Evidence Maturity: Exploratory (confirmed)
OpenClaw triage_score: 4 | Phase 2 composite: 4.3
Articles 52 & 53 — JAMA Multicancer early detection diagnostic delays (PMID 42804195, 42804225)
Both are title-only records with low classification confidence. Article 52 is a letter raising concerns about diagnostic delays in multicancer screening trials; Article 53 is the author reply. Both are important in the context of multicancer early detection test discourse, but without abstract content, independent scoring is severely limited.
| Dimension | Score (both) | Rationale |
|---|---|---|
| Scientific Novelty | 2 | Cannot assess without abstract |
| Clinical Relevance | 4 | Diagnostic delay in cancer screening is an important safety/quality concern |
| Population Reach | 5 | Multicancer early detection tests have broad population implications |
| Implementation Speed | 3 | Title-only; cannot assess |
| Evidence Strength | 1 | Title-only; low classification confidence; cannot exceed 3 on any dimension confidently |
Evidence Maturity: Exploratory (confirmed — title-only, low confidence)
🔴 OpenClaw triage_score: 3 | Phase 2 composite: 3.1 (both)